Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andy Lynn"'
Autor:
Kimberly J. Hassett, Kerry E. Benenato, Eric Jacquinet, Aisha Lee, Angela Woods, Olga Yuzhakov, Sunny Himansu, Jessica Deterling, Benjamin M. Geilich, Tatiana Ketova, Cosmin Mihai, Andy Lynn, Iain McFadyen, Melissa J. Moore, Joseph J. Senn, Matthew G. Stanton, Örn Almarsson, Giuseppe Ciaramella, Luis A. Brito
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 15, Iss , Pp 1-11 (2019)
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines.
Externí odkaz:
https://doaj.org/article/a67efab35a6f4ecb83f57432db8444c0
Autor:
Matt Theisen, Jaclyn Milton, Becca Levy, Ling Yin, Andrea Frassetto, Staci Sabnis, Vladimir Presnyak, Gilles Besin, Kerry Benenato, Timothy Salerno, Kristin E. Burke, Andy Lynn, Paolo Martini, Xuling Zhu, Patrick Finn, Christine Lukacs, Lin T. Guey, Summar Siddiqui, Jenny Zhuo, Joe Milano
Publikováno v:
The American Journal of Human Genetics. 104:625-637
Fabry disease is an X-linked lysosomal storage disease caused by loss of alpha galactosidase A (α-Gal A) activity and is characterized by progressive accumulation of globotriaosylceramide and its analogs in all cells and tissues. Although enzyme rep
Autor:
Aisha Lee, Kerry Benenato, Angela Woods, Cosmin Mihai, Luis Brito, Andy Lynn, Matthew G. Stanton, Orn Almarsson, Kimberly J. Hassett, Benjamin M. Geilich, Olga Yuzhakov, Sunny Himansu, Melissa J. Moore, Jessica Deterling, Joseph J. Senn, Tatiana Ketova, Iain Mcfadyen, Eric Jacquinet, Giuseppe Ciaramella
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 15, Iss, Pp 1-11 (2019)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines.
Autor:
Iain Mcfadyen, Kerry Benenato, Cosmin Mihai, Andy Lynn, Timothy Salerno, Matthew G. Stanton, Alex Bulychev, E. Sathyajith Kumarasinghe, Orn Almarsson, Tatiana Ketova, Joyce Chan, Staci Sabnis, Joseph J. Senn
The success of mRNA-based therapies depends on the availability of a safe and efficient delivery vehicle. Lipid nanoparticles have been identified as a viable option. However, there are concerns whether an acceptable tolerability profile for chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d901226f1c937f312227f83786157589
https://europepmc.org/articles/PMC5986714/
https://europepmc.org/articles/PMC5986714/
Autor:
Peter F Smith, Alex Bulychev, Stephen Hoge, Michael E Laska, Joseph J. Senn, Stefan Platz, Maja Sedic, Joseph Beene Bolen, Eric Jacquinet, Victoria Bartlett, Andy Lynn, Michael J. Smith
Publikováno v:
Veterinary pathology. 55(2)
The pharmacology, pharmacokinetics, and safety of modified mRNA formulated in lipid nanoparticles (LNPs) were evaluated after repeat intravenous infusion to rats and monkeys. In both species, modified mRNA encoding the protein for human erythropoieti
Autor:
Andy Lynn, Ling Yin, Gilles Besin, Xuling Zhu, Lin T. Guey, Kerry Benenato, Andrea Frassetto, Jenny Zhuo, Nancy M. Dahms, James J. Miller, Becca Levy, Summar Siddiqui, Christine Lukacs, Carly A Murphy, Joe Milano, Angela K. Beltrame, Paolo Martini, Vladimir Presnyak, Matt Theisen, Rebecca Howell
Publikováno v:
Molecular Genetics and Metabolism. 123:S153